secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-09-25T17:05:32+00:00
Accession:  0001437749-26-031199
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin preclinical data: Annamycin pancreatic cancer activity partly mediated by CD8+ T cells
--------------------------------------------------------------------------------

- Preclinical data: Annamycin's pancreatic cancer activity is partially mediated by CD8+ T cells, suggesting an immune-mediated mechanism beyond direct cytotoxicity.
- Data presented at AACR Conference on Pancreatic Cancer, Sept 25–28, 2026, at Hilton San Diego Bayfront; abstract published in Sept 15, 2026 Cancer Research supplement.
- Presenter: Angela T. Alistar, MD (Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center); abstract title: 'Turning cold pancreatic tumors hot'.
- Annamycin is not currently in clinical development for pancreatic cancer; lead program remains MIRACLE trial in relapsed/refractory AML, the basis of near-term milestones.
- CEO Walter Klemp: data point to 'unexpected additional benefit'; if observation holds, it broadens where Annamycin might be useful and how it might be combined.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/0001437749-26-031199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031199/mbrx20260924_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer